Driehaus Capital Management LLC Has $153.82 Million Holdings in Xenon Pharmaceuticals Inc. $XENE

Key Points

• Driehaus Capital Management LLC increased its holdings in Xenon Pharmaceuticals by 1.4%, now owning approximately 4.58 million shares valued at $153.8 million.
• Wall Street analysts show a consensus "Buy" rating for Xenon Pharmaceuticals with a target price averaging $53.20.
• Xenon Pharmaceuticals recently reported a quarterly loss of ($1.07) EPS, missing estimates, while its market cap stands at $2.98 billion.

Driehaus Capital Management LLC increased its position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 1.4% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 4,584,859 shares of the biopharmaceutical company's stock after purchasing an additional 64,264 shares during the quarter. Xenon Pharmaceuticals makes up 1.5% of Driehaus Capital Management LLC's holdings, making the stock its 4th largest position. Driehaus Capital Management LLC owned about 5.99% of Xenon Pharmaceuticals worth $153,822,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of XENE. Raymond James Financial Inc. bought a new stake in shares of Xenon Pharmaceuticals in the 4th quarter valued at about $797,000. Barclays PLC grew its stake in Xenon Pharmaceuticals by 20.9% in the 4th quarter. Barclays PLC now owns 18,127 shares of the biopharmaceutical company's stock valued at $711,000 after buying an additional 3,134 shares during the last quarter. Voya Investment Management LLC grew its stake in Xenon Pharmaceuticals by 32.3% in the 4th quarter. Voya Investment Management LLC now owns 62,415 shares of the biopharmaceutical company's stock valued at $2,447,000 after buying an additional 15,250 shares during the last quarter. Aquatic Capital Management LLC acquired a new position in Xenon Pharmaceuticals in the 4th quarter valued at about $324,000. Finally, Quarry LP acquired a new position in Xenon Pharmaceuticals in the 4th quarter valued at about $78,000. 95.45% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently commented on XENE. Wells Fargo & Company decreased their price target on shares of Xenon Pharmaceuticals from $50.00 to $47.00 and set an "overweight" rating on the stock in a research note on Tuesday, May 13th. Evercore ISI began coverage on shares of Xenon Pharmaceuticals in a research note on Wednesday, May 14th. They issued an "outperform" rating and a $55.00 price target on the stock. William Blair reiterated an "outperform" rating on shares of Xenon Pharmaceuticals in a research note on Monday, May 5th. Chardan Capital reiterated a "buy" rating and issued a $55.00 price target on shares of Xenon Pharmaceuticals in a research note on Tuesday, August 12th. Finally, Wall Street Zen lowered shares of Xenon Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Wednesday, May 21st. Eleven research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $53.20.

Xenon Pharmaceuticals Stock Performance

Shares of NASDAQ XENE traded up $0.11 during trading hours on Friday, hitting $38.71. 677,575 shares of the stock were exchanged, compared to its average volume of 977,838. The company has a market cap of $2.98 billion, a PE ratio of -10.90 and a beta of 1.17. The company's fifty day simple moving average is $33.83 and its two-hundred day simple moving average is $33.89. Xenon Pharmaceuticals Inc. has a 1-year low of $26.74 and a 1-year high of $46.00.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last issued its quarterly earnings data on Monday, August 11th. The biopharmaceutical company reported ($1.07) EPS for the quarter, missing the consensus estimate of ($1.03) by ($0.04). During the same quarter last year, the company earned ($0.75) EPS. As a group, sell-side analysts expect that Xenon Pharmaceuticals Inc. will post -3.1 EPS for the current fiscal year.

Xenon Pharmaceuticals Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.